2024-11-0920161007-932710.3748/wjg.v22.i11.31272-s2.0-84960863524https://hdl.handle.net/20.500.14288/3960Colorectal cancer metastasizes predictably, with liver predominance in most cases. Because liver involvement has been shown to be a major determinant of survival in this population, liver-directed therapies are increasingly considered even in cases where there is (limited) extrahepatic disease. Unfortunately, these patients carry a known risk of recurrence in the liver regardless of initial therapy choice. Therefore, there is a demand for minimally invasive, non-surgical, personalized cancer treatments to preserve quality of life in the induction, consolidation, and maintenance phases of cancer therapy. This report aims to review evidence-based conceptual, pharma cological, and technological paradigm shifts in parenteral and percutaneous treatment strategies as well as forthcoming evidence regarding next-generation systemic, locoregional, and local treatment approaches for this patient population.pdfMedicineGastroenterology and hepatologyJournal Article2219-2840https://doi.org/10.3748/wjg.v22.i11.3127372319300005N/ANOIR00400